Zinzino announced it has acquired the rights to Valentus Global’s distributor database and associated customer records, inventory and IP rights via an asset purchase. Though based in Delaware, much of Valentus’ operations and sales take place within European markets, and Zinzino expects the acquisition will bolster its distribution power across the region.
The partnership is part of a strategic pattern of acquisitions for Zinzino. In 2020, the company acquired VMA Life, followed by Enhanzz in 2022, Xelliss and ACN in 2024, and an asset acquisition of Zurvita in early 2025.
Zinzino will pay a total purchase price of approximately $2 million at closing, paid in cash and financed with its own cash.
The company described this recent acquisition as “another strategically important step in Zinzino’s growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales.”
